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The childhood cerebral form of adrenoleukodystrophy (ALD) causes rapid demyelination
of cerebral white matter and is clinically characterized by hyperactivity, emotional changes,
and poor school performance, as well as progressive cognitive, visual, auditory, speech, and
motor decline. While aggressive behavior is a known complication of ALD, treatment of the
disease is limited. Moreover, behavioral management is not well described in the available
literature, particularly from a psychiatric standpoint. In this case presentation, the patient’s
parents reported significant agitation and aggression, which may have been secondary to
verbal deficits, in addition to the general neuropathological implications of this disease.
Although this patient’s previously prescribed pharmacotherapy was controlling most of his
symptoms, the parents were understandably resistant to a treatment strategy that was
so sedating. Therefore, modifications in the patient’s original medical therapy were made,
including a 50% decrease in his risperidone dosage. He was also referred to a behavioral
therapist specializing in autism and speech therapy. He received Applied Behavior Analysis
therapy, which was modified to teach a simplified method of communication using shapes
identified by tactile sensation. At his 7-month follow-up, the parents reported noticeable
improvement in the child’s behavior and communication as well as fewer episodes of aggression. Quality of life is of the utmost importance for patients with such a limited life span.
Medical care must be individualized for patients with ALD in ways that will enhance their
quality of life, focusing on counseling, behavioral management, and interventions designed
to address communication difficulties and strengthen social relationships.
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Introduction

Adrenoleukodystrophy (ALD) is a rare disease,
affecting approximately 1 in 17000 newborns.1
Mutations in the ABCD1 gene lead to a defective peroxisomal protein known as the adrenoleukodystrophy protein (ALDP).2 ALDP is
responsible for transporting very-long-chain
fatty acids (VLCFAs) into the peroxisome for
beta-oxidation.3 The extracellular accumulation
of VLCFAs has direct cytotoxic effects due to
oxidative stress, and recent research shows
that ABCD1 gene mutations may also lead to
alterations in the brain cell junctions and bloodbrain barrier permeability.4,5 ALD may present

in different forms, including cerebral childhood
adrenoleukodystrophy (cALD), cerebral adult
form, adrenomyeloneuropathy (AMN), or Addison’s disease.6 The cerebral childhood form,
seen in this case, causes rapid demyelination
of cerebral white matter and is clinically characterized by hyperactivity, emotional changes,
poor school performance, and progressive
cognitive, visual, auditory, speech, and motor
decline.7 The cALD form has an extremely poor
prognosis, with symptoms onset around 4 to
10 years of age. Death usually occurs within 1 to
10 years of diagnosis depending on the severity
of the disease.8 In this case, the patient was
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diagnosed at age 9. The patient presented with
all of the aforementioned symptoms as well as
behavioral outbursts, which were the parents’
main concern at their psychiatry visit.
The primary treatment is bone marrow stem
cell transplantation, which has been found
to improve survivability, stabilize the disease
process, and prevent further deterioration in
neurological function in some cases.9 Patients
in the early stages of the disease have a 95%
5-year survival rate when treated with stem
cell therapy compared to a 54% 5-year survival rate among the untreated group (P=.006).9
Among those in the later stages of the disease,
careful consideration of stem cell transplants
is recommended, given the likelihood that the
procedure's risks would outweigh the benefits.
However, there is a paucity of literature describing the psychiatric implications of cALD
and associated treatment strategies. Behavioral issues are not only a concern in patients with
ALD but among many children with neurodegenerative disorders. Those who are also
visually impaired, as is often the case in ALD,
may exhibit challenges with regard to general
compliance, routine changes, and emotional
outbursts.10 Neurological diseases are often
entwined with psychiatric manifestations,
indicating that the biopsychosocial approach to
care cannot be exclusive to the field of psychiatry.11 Given that the symptoms experienced by
a child depend on their disease process, treatment plans must be developed and adapted to
their unique needs. The purpose of this case
report is to present the psychosocial needs of
a child with ALD and demonstrate an approach
to psychiatric care that prioritizes quality of life
for both the patient and family.

Case Description

A 9-year-old, 31.6 kilogram male with otherwise
normal development initially presented to the
pediatrician’s office due to hearing loss concerns. Cerumen impaction was found bilaterally. However, upon removal, the patient still
failed a hearing test. The pediatrician referred
the patient to the hospital for magnetic resonance imaging (MRI) as the hearing loss had
progressed over the past 4 to 5 months. The
parents had also recently noted horizontal gaze
deviation, difficulty understanding words, poor
attention and concentration, and behavioral
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changes, including irritability, echolalia, and
a decline in school grades. The patient was
undergoing a workup for attention-deficit/hyperactivity disorder (ADHD) when a brain MRI
revealed active demyelinating processes in the
posterior deep white matter and corticospinal
tracts. The patient was scheduled for an appointment at a genetics and metabolism clinic.
He was diagnosed with X-linked ALD within
weeks. After the diagnosis, the patient began
hematopoietic stem cell transplant therapy
within the year, but the disease progressed. He
developed adrenal insufficiency and difficulty
swallowing, leading to G-tube placement. He
also experienced vision loss, seizures, and continued neurological deterioration.
Six years later, at age 15, the patient presented
to the children’s psychiatry clinic, where the
parents reported significant behavioral changes. The father noted that the stem cell therapy
had slowed some aspects of the disease, but
the patient was becoming easily agitated and
increasingly aggressive. Outbursts often occured in the mornings and in response to loud
noises, usually caused by his 2 siblings, both of
whom had been diagnosed with ADHD. When
frustrated, the patient was known to slam
doors, hit, kick, and pinch, as evidenced by several small dark ecchymoses along the father’s
forearms. His aggressive behavior resulted in
his withdrawal from school. Most recently, the
patient has begun reaching for and twisting
the nipples of his caretakers, a behavior whose
origins the parents could not determine.
On admission to the hospital due to a behavioral outburst, the patient was found to be
constipated on abdominal radiographs. An
X-ray showed moderate stool burden, and the
stool caliber was Bristol scale type 1, indicating
severe constipation. Upon receiving treatment
for constipation, his irritability decreased. At
the time of admission, the patient’s psychiatric
medications included risperidone 2 mg twice
daily with 4 mg pro re nata (PRN), diphenhydramine 25 mg daily, sertraline 76 mg daily, and
levetiracetam 850 mg daily, for seizure control.
Given his deteriorating behavior on the current
therapy, his medications were changed during
admission, including the discontinuation of
diphenhydramine, the addition of clonazepam
0.5 mg twice daily, an increase in sertraline to
100 mg daily, and a decrease in the PRN dose of
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risperidone to 2 mg. Additionally, due to known
behavioral side effects, levetiracetam was transitioned to oxcarbazepine.

Treatment

At the time of presentation to the psychiatry
clinic, the patient was on risperidone 4 mg
twice daily, with 2 mg PRN, oxcarbazepine 600
mg every morning and 300 mg every night,
sertraline 76 mg daily, and clonazepam 0.5
mg twice daily for behavioral issues. Since his
hospitalization for constipation 2 months previously, his medications were changed slightly
in a further attempt to manage his behavior, including an increase in risperidone and a
decrease in sertraline. Although this medical
therapy was controlling most of his symptoms,
his parents were understandably resistant to a
treatment strategy that was so sedating. His
social interactions were limited, and he was becoming less responsive to redirection. Additionally, it was hypothesized that his outbursts may
have been due in part to an inability to communicate his distress. For example, his irritability
seemed to be attributable to the discomfort
of constipation. Quality of life is of the utmost
importance for a patient with such a limited life
span. Therefore, the patient was continued on
pharmaceutical therapy with a decrease in his
risperidone dosage to 2 mg twice daily with 2
mg to use PRN. He was also referred to physical therapy, occupational therapy, and a behavioral therapist specializing in autism and speech
therapy. The patient received Applied Behavior
Analysis (ABA) therapy (45 minutes per session,
twice weekly) that was modified to teach him
to communicate with shapes, given his other
sensory deficits. Objects of different shapes
were slowly introduced and used to represent
his needs, which he identified by touch and put
in a plastic jar. For example, a circle represented
food concerns, and a square represented toy
concerns. Given his history of aggressive outbursts when frustrated, a triangle was introduced to represent his need for personal space.
The parents were also included in the therapy
so they could learn management techniques
that avoided reinforcing negative behaviors,
such as avoiding comforting the patient during
instances of aggression.

Outcome and Follow-up

Given the understandable stress that the

family was under, as well as their need for
multidisciplinary medical care in multiple cities,
psychiatric follow-up was difficult to maintain.
However, at the 7-month follow-up, the patient
returned to the clinic with significant improvement in symptoms. His parents noted improvements in mood, aggression levels, and sleep.
In fact, the patient had not required another
hospitalization for behavioral events since his
last visit. His communication skills were also
developing with the behavioral therapy, which
he had received for the past 6 months. At the
time of his visit, the therapy was stopped temporarily due to insurance issues. Although his
progress was slow, the patient had a recent example of improved communication strategies.
In the past, he had become frustrated when his
mother assisted him with putting on his socks,
resulting in outbursts of hitting or pushing.
Now, the patient’s mother would place the
shapes near him when helping with this task,
then watch to see if he placed the triangle in
the bucket, thereby communicating his need
for space and independence. The only change
made to his medications since his last visit
was an increase in his oxcarbazepine dose by
his neurologist from a total of 900 mg to 1020
mg daily due to a seizure occurring 3 months
ago. Given the significant improvement in
the patient’s symptoms and quality of life, his
medical, physical, occupational, and behavioral
therapies were continued pending insurance
authorization. Family therapy was also recommended to improve intrafamilial relationships
and address feelings of anxiety expressed by
the patient’s parents. Another follow-up appointment was scheduled 6 weeks out.

Discussion

While aggressive behavior is a known complication of ALD,12 options for treatment of the
disease are limited and behavioral management
is not well described in the available literature,
particularly from a psychiatric standpoint.13 In
other case reports, risperidone has been used
to treat disruptive behavior,14 while valproate
has been used to control manic-like behavioral
changes.13 However, the use of these anticholinergics and antipsychotics in some cases may do
more harm than good, resulting in a variety of
side effects with minimal improvement in the
psychiatric symptoms.15 Dose-related neurological side effects of these medications, such
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as impairments in concentration, memory, and
attention, are particularly undesirable, especially for a patient with limited cognitive function.16
Aggressive behavior is not a clinical presentation unique to ALD, especially since psychiatric
and neurological diseases often overlap. Among
the psychiatric and behavioral comorbidities associated with childhood neurological diseases,
autism spectrum disorder (ASD) is especially
frequent.17 ASD and its subtypes have been implicated in children with cerebral palsy, epilepsy,
learning disabilities, speech impairments, and
a broad range of genetic and metabolic diseases.17,18 In many cases, ASD is secondary to the
underlying disease process, rather than coincidental.19 One study showed that almost 50%
of all admissions to psychiatric inpatient units
among children and adolescents were due to
aggression.20 The study found that a standardized behavioral management plan significantly
decreased aggressive incidents, injuries, and
the necessity of physical restraint. In addition,
the extent of expressive language deficits was
found to be positively correlated with levels of
aggression in children who have experienced
physical abuse.21 Verbal deficits can cause children to express themselves through physical
actions.22 For that reason, developing strategies to improve communication and behavior
is vital to help children express themselves in
healthier ways. ABA-based interventions have
been found to improve communication and
expression in patients with autism.23 However,
there is no available literature regarding the
use of ABA for patients with adrenoleukodystrophy to the authors’ knowledge. In this case,
ABA was adapted to include the use of shapes,
identified by feel, to indicate various needs.
This simplified communication strategy is also
minimally studied in the literature, with the
majority of research surrounding more complex
tactile communication methods such as Braille
and American Sign Language. However, these
communication methods were not appropriate
in this case given the patient’s neurological and
sensory deficits.
Care must also be taken to address the underlying issues that may be contributing to
a child’s behavior. A revised consensus statement regarding the care of individuals with
leukodystrophies emphasizes the importance
of identifying mood disorders, pain, irritability,
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and sleep disturbances among these patients.24
Targeting the underlying causes of these symptoms is critical to improving the quality of life
for the patient as well as their caregivers. In
this case, recognizing and treating the patient’s
constipation had a significant impact on his
comfort and, therefore, his behavior.
Suggested strategies for managing behavior
among visually impaired children with neurodegenerative disorders include: involving
the child in decisions regarding their activities, developing schedules and routines, using
physical prompts as reminders and guides, and
acknowledging their fears and frustrations.10
Integrating these strategies can become even
more complicated with a patient who also has
auditory and verbal impairments. A Cochrane
review looking at communication interventions
for minimally verbal children with ASD found
that verbal- and picture-based interventions
demonstrated no significant improvement in
communication outcomes over time.25 However, the review was quite limited by strict inclusion criteria and only assessed the results of 2
studies. Although they identified other, smaller
studies that may have shown communication
improvements, those studies were excluded
due to a lack of control groups. In patients
with Down syndrome, the use of both Natural
Language Paradigm and Milieu Communication
therapy strategies have shown efficacy in improving communication skills.26 Both methods
prioritize altering the environment to encourage communication and interaction. For example, a child’s progression through an enjoyable
activity is determined by the child’s initiative to
communicate.
Finally, in cases of chronic illness, care must
also be offered to the patient’s caretakers. A
2019 systematic review found that psychotherapeutic interventions, specifically cognitive-behavioral therapy (CBT) and problem-solving
therapy (PST) have been found to improve
mental health and behaviors in parents caring
for children with chronic illnesses.27 In fact,
CBT may also improve children’s behaviors
and symptoms. Although the authors found
minimal literature regarding family therapy,27
there is some evidence that it is effective for
families of children suffering from chronic
diseases, including asthma and diabetes mellitus, by decreasing parental stress and improv-
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ing intrafamilial relationships.28,29 Involving the
family in the treatment plan has been shown to
improve treatment compliance and outcomes
by allowing parents to become more engaged
in their child’s care and creating a better home
environment.30 In this case, teaching the parents to avoid reinforcing negative behaviors
was instrumental to maintaining consistency in
behavioral adaptations.

Conclusion

The psychiatric and social impacts of ALD cannot be overlooked. Behavioral changes significantly impact the quality of life of the patient,
their family members, and their relationships
with others. The lack of a standardized treatment algorithm makes medical management
challenging, especially in cases where the
patient faces a poor prognosis. Efforts need
to be made to refine pharmacotherapy for
patients in ways that address their symptoms
while minimizing dose-related side effects,
such as those associated with antipsychotics. It
is also imperative that patients with neurocognitive disorders and their families are provided
with multidisciplinary, holistic care, including
counseling and related resources designed to
maximize their quality of life, improve communication strategies, and strengthen social
relationships. In cases where patients face
comprehensive neurological and sensory deficits but maintain haptic competence, simplified
communication strategies using shapes are a
possible solution.

Acknowledgments

The authors wish to thank the patient and his
family for sharing their story. We would also
like to thank Dr Aleli Campbell for her advice
and guidance.

Conflicts of Interest

The authors declare that they have no conflicts
of interest.
1.

Author Affiliations

Department of Psychiatry, Texas Tech
University Health Sciences Center El Paso,
El Paso, TX

References
1.

Bezman L, Moser AB, Raymond GV, et al. Adrenoleukodystrophy: incidence, new mutation rate,

and results of extended family screening. Ann
Neurol. 2001;49(4):512-517. doi:10.1002/ana.101
2. Mosser J, Lutz Y, Stoeckel ME, et al. The
gene responsible for adrenoleukodystrophy
encodes a peroxisomal membrane protein.
Hum Mol Genet. 1994;3(2):265-271. doi:10.1093/
hmg/3.2.265
3. Singh I, Moser AE, Moser HW, Kishimoto
Y. Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white
blood cells, cultured skin fibroblasts, and
amniocytes. Pediatr Res. 1984;18(3):286-290.
doi:10.1203/00006450-198403000-00016
4. Kemp S, Huffnagel IC, Linthorst GE, Wanders
RJ, Engelen M. Adrenoleukodystrophy-neuroendocrine pathogenesis and redefinition of natural history. Nat Rev Endocrinol.
2016;12(10):606-615. doi:10.1038/nrendo.2016.90
5. Musolino PL, Gong Y, Snyder JM, et al. Brain
endothelial dysfunction in cerebral adrenoleukodystrophy. Brain. 2015;138(Pt 11):3206-3220.
doi:10.1093/brain/awv250
6. Ferrer I, Aubourg P, Pujol A. General aspects
and neuropathology of X-linked adrenoleukodystrophy. Brain Pathol. 2010;20(4):817-830.
doi:10.1111/j.1750-3639.2010.00390.x
7. Miller WP, Rothman SM, Nascene D, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort
report. Blood. 2011;118(7):1971-1978. doi:10.1182/
blood-2011-01-329235
8. National Institute of Neurological Disorders and
Stroke. Adrenoleukodystrophy. U.S. Department
of Health and Human Services; 2019. Accessed,
February 3, 2022. https://www.ninds.nih.gov/
health-information/disorders/adrenoleukodystrophy
9. Mahmood A, Raymond GV, Dubey P, Peters C,
Moser HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral
X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol. 2007;6(8):687-692.
doi:10.1016/S1474-4422(07)70177-1
10. Loftin MM, Koehler WS. Proactive strategies
for managing the behavior of children with
neurodegenerative diseases and visual impairment. J Vis Impair Blind. 1998;92(1):55-62.
doi:10.1177/0145482X9809200108
11. Baird G, Santosh PJ. Interface between neurology and psychiatry in childhood. J Neurol
Neurosurg Psychiatry. 2003;74(Suppl 1):i17-i22.
doi:10.1136/jnnp.74.suppl_1.i17
12. Moser HW, Smith KD, Watkins PA, Powers J,
Moser AB. X-linked adrenoleukodystrophy. In:
Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The
Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill; 2001:3257–3301.

261

HCA Healthcare Journal of Medicine

13. Salsano E, Gambini O, Giovagnoli AR, Farina
L, Uziel G, Pareyson D. Effectiveness of valproate for the treatment of manic-like behavior
in X-linked adrenoleukodystrophy. Neurol Sci.
2012;33(5):1197-1199. doi:10.1007/s10072-011-0863-2
14. Ilango TS, Nambi S. X-linked adrenoleukodystrophy presenting as attention deficit hyperactivity
disorder. Indian J Psychiatry. 2015;57(2):208-209.
doi:10.4103/0019-5545.158198
15. Garside S, Rosebush PI, Levinson AJ, Mazurek
MF. Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms. J
Clin Psychiatry. 1999;60(7):460-468. doi:10.4088/
jcp.v60n0708
16. Lieberman JA 3rd. Managing anticholinergic side
effects. Prim Care Companion J Clin Psychiatry.
2004;6(Suppl 2):20-23.
17. Gillberg C. Double syndromes: autism associated with genetic, medical and metabolic disorders. In: Nass R, Frank Y, eds.
Cognitive and Behavioral Abnormalities of
Pediatric Diseases. Oxford University Press;
2010. Accessed March 24, 2022. doi: 10.1093/
oso/9780195342680.003.0008
18. Kilincaslan A, Mukaddes NM. Pervasive developmental disorders in individuals with cerebral
palsy. Dev Med Child Neurol. 2009;51(4):289-294.
doi:10.1111/j.1469-8749.2008.03171.x
19. Levy SE, Giarelli E, Lee LC, et al. Autism spectrum disorder and co-occurring developmental, psychiatric, and medical conditions among
children in multiple populations of the United
States. J Dev Behav Pediatr. 2010;31(4):267-275.
doi:10.1097/DBP.0b013e3181d5d03b
20. Dean AJ, Duke SG, George M, Scott J. Behavioral management leads to reduction in
aggression in a child and adolescent psychiatric inpatient unit. J Am Acad Child Adolesc
Psychiatry. 2007;46(6):711-720. doi:10.1097/
chi.0b013e3180465a1a
21. Burke AE, Crenshaw DA, Green J, Schlosser MA,
Strocchia-Rivera L. Influence of verbal ability
on the expression of aggression in physically
abused children. J Am Acad Child Adolesc Psychiatry. 1989;28(2):215-218. doi:10.1097/00004583198903000-00011
22. Charman T, Ricketts J, Dockrell JE, Lindsay G,
Palikara O. Emotional and behavioural problems in children with language impairments
and children with autism spectrum disorders.
Int J Lang Commun Disord. 2015;50(1):84-93.
doi:10.1111/1460-6984.12116
23. Yu Q, Li E, Li L, Liang W. Efficacy of interventions based on applied behavior analysis for
autism spectrum disorder: a meta-analysis. Psychiatry Investig. 2020;17(5):432-443. doi:10.30773/
pi.2019.0229

262

24. Adang LA, Sherbini O, Ball L, et al. Revised
consensus statement on the preventive and
symptomatic care of patients with leukodystrophies. Mol Genet Metab. 2017;122(1-2):18-32.
doi:10.1016/j.ymgme.2017.08.006
25. Brignell A, Chenausky KV, Song H, Zhu J, Suo
C, Morgan AT. Communication interventions
for autism spectrum disorder in minimally
verbal children. Cochrane Database Syst Rev.
2018;11(11):CD012324. doi:10.1002/14651858.
CD012324.pub2
26. Neil N, Jones EA. Communication intervention
for individuals with Down syndrome: systematic review and meta-analysis. Dev Neurorehabil.
2018;21(1):1-12. doi:10.1080/17518423.2016.1212947
27. Law E, Fisher E, Eccleston C, Palermo TM.
Psychological interventions for parents of children and adolescents with chronic illness. Cochrane Database Syst Rev. 2019;3(3):CD009660.
doi:10.1002/14651858.CD009660.pub4
28. Yeh HY, Ma WF, Huang JL, Hsueh KC, Chiang
LC. Evaluating the effectiveness of a family
empowerment program on family function
and pulmonary function of children with asthma: a randomized control trial. Int J Nurs Stud.
2016;60:133-144. doi:10.1016/j.ijnurstu.2016.04.013
29. Wysocki T, Harris MA, Greco P, et al. Randomized, controlled trial of behavior therapy
for families of adolescents with insulin-dependent diabetes mellitus. J Pediatr Psychol.
2000;25(1):23-33. doi:10.1093/jpepsy/25.1.23
30. Diamond G, Josephson A. Family-based treatment research: a 10-year update. J Am Acad
Child Adolesc Psychiatry. 2005;44(9):872-887.
doi:10.1097/01.chi.0000169010.96783.4e

